| Outcomes . | Number of strata . | Number of studies . | Number of participants (intervention: Control) . | Effect estimates (95% CI), P-value . | I2 (%) . | Publication bias (95% CI), P-value . |
|---|---|---|---|---|---|---|
| SBP, mmHg | 60 | 59 | 9837 (5447: 5316) | −0.70 (−1.59, 0.19), P = .124 | 74 | 0.17 (−0.87, 1.21), P = .754 |
| DBP, mmHg | 59 | 58 | 9777 (5417: 5286) | −0.30 (−0.66, 0.06), P = .106 | 24 | −0.04 (−0.55, 0.63), P = .894 |
| TG, mmol/L | 100 | 99 | 7715 (4844: 4535) | −0.06 (−0.08, −0.04), P < .001 | 96 | −0.24 (−0.65, 0.17), P = .252 |
| TC, mmol/L | 101 | 99 | 7083 (4552: 4255 | −0.12 (−0.17, −0.08), P < .001 | 89 | −0.16 (−0.97, 0.64), P = .689 |
| LDL-C, mmol/L | 101 | 99 | 7114 (4561: 4277) | −0.11 (−0.14, −0.08), P < .001 | 90 | −0.08 (−0.70, 0.53), P = .785 |
| HDL-C, mmol/L | 101 | 99 | 7689 (4848: 4565) | 0.01 (−0.00, 0.03), P = .072 | 98 | −0.08 (−0.71, 0.55), P = .798 |
| VLDL-C, mmol/L | 24 | 24 | 1792 (1226:1145) | −0.04 (−0.06, −0.02), P < .001 | 42 | −0.47 (−1.40, 0.46), P = .322 |
| IDL-C, mmol/L | 5 | 5 | 266 (189: 190) | −0.02 (−0.04, 0.01), P = .135 | 40 | −2.59 (−5.02, −0.17), P = .036 |
| Non-HDL-C, mmol/L | 21 | 21 | 1480 (1084: 981) | −0.20 (−0.27, −0.14), P < .001 | 73 | 0.09 (−1.08, 1.26), P = .885 |
| Apo A1, g/L | 28 | 28 | 1851 (1223: 1178) | −0.00 (−0.01, 0.01), P = .395 | 30 | 0.30 (−0.47, 1.06), P = .445 |
| Apo B, g/L | 34 | 34 | 2344 (1663: 1609) | −0.03 (−0.05, −0.02), P < .001 | 76 | 0.50 (−0.48, 1.48), P = .320 |
| Lp(a), g/L | 12 | 12 | 1193 (806: 816) | 0.00 (0.00, 0.01), P = .023 | 0 | −0.35 (−1.08, 0.39), P = .355 |
| Outcomes . | Number of strata . | Number of studies . | Number of participants (intervention: Control) . | Effect estimates (95% CI), P-value . | I2 (%) . | Publication bias (95% CI), P-value . |
|---|---|---|---|---|---|---|
| SBP, mmHg | 60 | 59 | 9837 (5447: 5316) | −0.70 (−1.59, 0.19), P = .124 | 74 | 0.17 (−0.87, 1.21), P = .754 |
| DBP, mmHg | 59 | 58 | 9777 (5417: 5286) | −0.30 (−0.66, 0.06), P = .106 | 24 | −0.04 (−0.55, 0.63), P = .894 |
| TG, mmol/L | 100 | 99 | 7715 (4844: 4535) | −0.06 (−0.08, −0.04), P < .001 | 96 | −0.24 (−0.65, 0.17), P = .252 |
| TC, mmol/L | 101 | 99 | 7083 (4552: 4255 | −0.12 (−0.17, −0.08), P < .001 | 89 | −0.16 (−0.97, 0.64), P = .689 |
| LDL-C, mmol/L | 101 | 99 | 7114 (4561: 4277) | −0.11 (−0.14, −0.08), P < .001 | 90 | −0.08 (−0.70, 0.53), P = .785 |
| HDL-C, mmol/L | 101 | 99 | 7689 (4848: 4565) | 0.01 (−0.00, 0.03), P = .072 | 98 | −0.08 (−0.71, 0.55), P = .798 |
| VLDL-C, mmol/L | 24 | 24 | 1792 (1226:1145) | −0.04 (−0.06, −0.02), P < .001 | 42 | −0.47 (−1.40, 0.46), P = .322 |
| IDL-C, mmol/L | 5 | 5 | 266 (189: 190) | −0.02 (−0.04, 0.01), P = .135 | 40 | −2.59 (−5.02, −0.17), P = .036 |
| Non-HDL-C, mmol/L | 21 | 21 | 1480 (1084: 981) | −0.20 (−0.27, −0.14), P < .001 | 73 | 0.09 (−1.08, 1.26), P = .885 |
| Apo A1, g/L | 28 | 28 | 1851 (1223: 1178) | −0.00 (−0.01, 0.01), P = .395 | 30 | 0.30 (−0.47, 1.06), P = .445 |
| Apo B, g/L | 34 | 34 | 2344 (1663: 1609) | −0.03 (−0.05, −0.02), P < .001 | 76 | 0.50 (−0.48, 1.48), P = .320 |
| Lp(a), g/L | 12 | 12 | 1193 (806: 816) | 0.00 (0.00, 0.01), P = .023 | 0 | −0.35 (−1.08, 0.39), P = .355 |
Abbreviations: Apo, apolipoprotein; CI, confidence interval; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein—cholesterol; IDL-C, intermediate-density lipoprotein—cholesterol; LDL-C, low-density lipoprotein—cholesterol; Lp, lipoprotein; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; VLDL-C, very low-density lipoprotein—cholesterol.
| Outcomes . | Number of strata . | Number of studies . | Number of participants (intervention: Control) . | Effect estimates (95% CI), P-value . | I2 (%) . | Publication bias (95% CI), P-value . |
|---|---|---|---|---|---|---|
| SBP, mmHg | 60 | 59 | 9837 (5447: 5316) | −0.70 (−1.59, 0.19), P = .124 | 74 | 0.17 (−0.87, 1.21), P = .754 |
| DBP, mmHg | 59 | 58 | 9777 (5417: 5286) | −0.30 (−0.66, 0.06), P = .106 | 24 | −0.04 (−0.55, 0.63), P = .894 |
| TG, mmol/L | 100 | 99 | 7715 (4844: 4535) | −0.06 (−0.08, −0.04), P < .001 | 96 | −0.24 (−0.65, 0.17), P = .252 |
| TC, mmol/L | 101 | 99 | 7083 (4552: 4255 | −0.12 (−0.17, −0.08), P < .001 | 89 | −0.16 (−0.97, 0.64), P = .689 |
| LDL-C, mmol/L | 101 | 99 | 7114 (4561: 4277) | −0.11 (−0.14, −0.08), P < .001 | 90 | −0.08 (−0.70, 0.53), P = .785 |
| HDL-C, mmol/L | 101 | 99 | 7689 (4848: 4565) | 0.01 (−0.00, 0.03), P = .072 | 98 | −0.08 (−0.71, 0.55), P = .798 |
| VLDL-C, mmol/L | 24 | 24 | 1792 (1226:1145) | −0.04 (−0.06, −0.02), P < .001 | 42 | −0.47 (−1.40, 0.46), P = .322 |
| IDL-C, mmol/L | 5 | 5 | 266 (189: 190) | −0.02 (−0.04, 0.01), P = .135 | 40 | −2.59 (−5.02, −0.17), P = .036 |
| Non-HDL-C, mmol/L | 21 | 21 | 1480 (1084: 981) | −0.20 (−0.27, −0.14), P < .001 | 73 | 0.09 (−1.08, 1.26), P = .885 |
| Apo A1, g/L | 28 | 28 | 1851 (1223: 1178) | −0.00 (−0.01, 0.01), P = .395 | 30 | 0.30 (−0.47, 1.06), P = .445 |
| Apo B, g/L | 34 | 34 | 2344 (1663: 1609) | −0.03 (−0.05, −0.02), P < .001 | 76 | 0.50 (−0.48, 1.48), P = .320 |
| Lp(a), g/L | 12 | 12 | 1193 (806: 816) | 0.00 (0.00, 0.01), P = .023 | 0 | −0.35 (−1.08, 0.39), P = .355 |
| Outcomes . | Number of strata . | Number of studies . | Number of participants (intervention: Control) . | Effect estimates (95% CI), P-value . | I2 (%) . | Publication bias (95% CI), P-value . |
|---|---|---|---|---|---|---|
| SBP, mmHg | 60 | 59 | 9837 (5447: 5316) | −0.70 (−1.59, 0.19), P = .124 | 74 | 0.17 (−0.87, 1.21), P = .754 |
| DBP, mmHg | 59 | 58 | 9777 (5417: 5286) | −0.30 (−0.66, 0.06), P = .106 | 24 | −0.04 (−0.55, 0.63), P = .894 |
| TG, mmol/L | 100 | 99 | 7715 (4844: 4535) | −0.06 (−0.08, −0.04), P < .001 | 96 | −0.24 (−0.65, 0.17), P = .252 |
| TC, mmol/L | 101 | 99 | 7083 (4552: 4255 | −0.12 (−0.17, −0.08), P < .001 | 89 | −0.16 (−0.97, 0.64), P = .689 |
| LDL-C, mmol/L | 101 | 99 | 7114 (4561: 4277) | −0.11 (−0.14, −0.08), P < .001 | 90 | −0.08 (−0.70, 0.53), P = .785 |
| HDL-C, mmol/L | 101 | 99 | 7689 (4848: 4565) | 0.01 (−0.00, 0.03), P = .072 | 98 | −0.08 (−0.71, 0.55), P = .798 |
| VLDL-C, mmol/L | 24 | 24 | 1792 (1226:1145) | −0.04 (−0.06, −0.02), P < .001 | 42 | −0.47 (−1.40, 0.46), P = .322 |
| IDL-C, mmol/L | 5 | 5 | 266 (189: 190) | −0.02 (−0.04, 0.01), P = .135 | 40 | −2.59 (−5.02, −0.17), P = .036 |
| Non-HDL-C, mmol/L | 21 | 21 | 1480 (1084: 981) | −0.20 (−0.27, −0.14), P < .001 | 73 | 0.09 (−1.08, 1.26), P = .885 |
| Apo A1, g/L | 28 | 28 | 1851 (1223: 1178) | −0.00 (−0.01, 0.01), P = .395 | 30 | 0.30 (−0.47, 1.06), P = .445 |
| Apo B, g/L | 34 | 34 | 2344 (1663: 1609) | −0.03 (−0.05, −0.02), P < .001 | 76 | 0.50 (−0.48, 1.48), P = .320 |
| Lp(a), g/L | 12 | 12 | 1193 (806: 816) | 0.00 (0.00, 0.01), P = .023 | 0 | −0.35 (−1.08, 0.39), P = .355 |
Abbreviations: Apo, apolipoprotein; CI, confidence interval; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein—cholesterol; IDL-C, intermediate-density lipoprotein—cholesterol; LDL-C, low-density lipoprotein—cholesterol; Lp, lipoprotein; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; VLDL-C, very low-density lipoprotein—cholesterol.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
